Citation
Pinto, Dora, et al. "Cross-neutralization of SARS-CoV-2 By a Human Monoclonal SARS-CoV Antibody." Nature, vol. 583, no. 7815, 2020, pp. 290-295.
Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290-295.
Pinto, D., Park, Y. J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., Peter, A., Guarino, B., Spreafico, R., Cameroni, E., Case, J. B., Chen, R. E., Havenar-Daughton, C., Snell, G., Telenti, A., ... Corti, D. (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 583(7815), 290-295. https://doi.org/10.1038/s41586-020-2349-y
Pinto D, et al. Cross-neutralization of SARS-CoV-2 By a Human Monoclonal SARS-CoV Antibody. Nature. 2020;583(7815):290-295. PubMed PMID: 32422645.
TY - JOUR
T1 - Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
AU - Pinto,Dora,
AU - Park,Young-Jun,
AU - Beltramello,Martina,
AU - Walls,Alexandra C,
AU - Tortorici,M Alejandra,
AU - Bianchi,Siro,
AU - Jaconi,Stefano,
AU - Culap,Katja,
AU - Zatta,Fabrizia,
AU - De Marco,Anna,
AU - Peter,Alessia,
AU - Guarino,Barbara,
AU - Spreafico,Roberto,
AU - Cameroni,Elisabetta,
AU - Case,James Brett,
AU - Chen,Rita E,
AU - Havenar-Daughton,Colin,
AU - Snell,Gyorgy,
AU - Telenti,Amalio,
AU - Virgin,Herbert W,
AU - Lanzavecchia,Antonio,
AU - Diamond,Michael S,
AU - Fink,Katja,
AU - Veesler,David,
AU - Corti,Davide,
Y1 - 2020/05/18/
PY - 2020/4/6/received
PY - 2020/5/12/accepted
PY - 2020/5/19/pubmed
PY - 2020/7/14/medline
PY - 2020/5/19/entrez
SP - 290
EP - 295
JF - Nature
JO - Nature
VL - 583
IS - 7815
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease.
SN - 1476-4687
UR - https://www.unboundmedicine.com/medline/citation/32422645/Cross_neutralization_of_SARS_CoV_2_by_a_human_monoclonal_SARS_CoV_antibody_
DB - PRIME
DP - Unbound Medicine
ER -